De-Risking Drug Discovery with Applied BioMath Assess™ - An Early Feasibility Assessment Tool for Biotherapeutics
June 9, 2021
It is well recognized that developing new therapeutics is costly and time-intensive, often requiring upwards of 10 years and investment of as much as two billion USD to take a new therapeutic to market. Early feasibility assessment (EFA) has proven to drastically improve the efficiency of pharmaceutical R&D and should be integrated into every drug R&D program. Applied BioMath Assess*, a new web-based application that provides the necessary models and analyses via an intuitive interface, makes this integration a reality.